Molecular Oncology
Volume 1, Issue 2 , Pages 205-215 , September 2007

Identification of alternatively spliced TIMP-1 mRNA in cancer cell lines and colon cancer tissue

  • P.A. Usher

      Affiliations

    • Department of Veterinary Pathobiology, Faculty of Life Sciences, University of Copenhagen, Ridebanevej 9, 1870 Frederiksberg C, Denmark
    • ,
  • A.M. Sieuwerts

      Affiliations

    • Department of Medical Oncology, Erasmus Medical Centre, Rotterdam, The Netherlands
    • ,
  • A. Bartels

      Affiliations

    • Department of Veterinary Pathobiology, Faculty of Life Sciences, University of Copenhagen, Ridebanevej 9, 1870 Frederiksberg C, Denmark
    • ,
  • U. Lademann

      Affiliations

    • Department of Veterinary Pathobiology, Faculty of Life Sciences, University of Copenhagen, Ridebanevej 9, 1870 Frederiksberg C, Denmark
    • ,
  • H.J. Nielsen

      Affiliations

    • Department of Surgical Gastroenterology, University Hospital Hvidovre, Denmark
    • ,
  • L. Holten-Andersen

      Affiliations

    • Department of Veterinary Pathobiology, Faculty of Life Sciences, University of Copenhagen, Ridebanevej 9, 1870 Frederiksberg C, Denmark
    • ,
  • J.A. Foekens

      Affiliations

    • Department of Medical Oncology, Erasmus Medical Centre, Rotterdam, The Netherlands
    • ,
  • N. Brünner

      Affiliations

    • Department of Veterinary Pathobiology, Faculty of Life Sciences, University of Copenhagen, Ridebanevej 9, 1870 Frederiksberg C, Denmark
    • ,
  • H. Offenberg

      Affiliations

    • Department of Veterinary Pathobiology, Faculty of Life Sciences, University of Copenhagen, Ridebanevej 9, 1870 Frederiksberg C, Denmark
    • Corresponding Author InformationCorresponding author. Tel.: +45 35283171; fax: +45 35353514.

Received 15 January 2007 ,Revised 2 May 2007 ,Accepted 7 May 2007.

References 

  1. Akahane T, Akahane M, Shah A, Connor CM, Thorgeirsson UP. TIMP-1 inhibits microvascular endothelial cell migration by MMP-dependent and MMP-independent mechanisms. Exp. Cell Res. 2004;301:158–167
  2. Baker AH, Edwards DR, Murphy G. Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J. Cell Sci. 2002;115:3719–3727
  3. Bertaux B, Hornebeck W, Eisen AZ, Dubertret L. Growth stimulation of human keratinocytes by tissue inhibitor of metalloproteinases. J. Investig. Dermatol. 1991;97:679–685
  4. Bodden MK, Harber GJ, Birkedal-Hansen B, Windsor LJ, Caterina NC, Engler JA, et al. Functional domains of human TIMP-1 (tissue inhibitor of metalloproteinases). J. Biol. Chem. 1994;269:18943–18952
  5. Brew K, Dinakarpandian D, Nagase H. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim. Biophys. Acta. 2000;1477:267–283
  6. Brunner N, Thompson EW, Spang-Thomsen M, Rygaard J, Dano K, Zwiebel JA. lacZ transduced human breast cancer xenografts as an in vivo model for the study of invasion and metastasis. Eur. J. Cancer. 1992;28A:1989–1995
  7. Davidsen LM, Würtz SO, Romer MU, Moller SN, Johansen SK, Christensen IJ, et al. TIMP-1 gene deficiency increases tumor cell sensitivity to chemotherapy-induced apoptosis. Br. J. Cancer. October 23, 2006;95(8):1114–1120
  8. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer. 2002;2:161–174
  9. Gomez DE, Alonso DF, Yoshiji H, Thorgeirsson UP. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur. J. Cell Biol. 1997;74:111–122
  10. Guedez L, Stetler-Stevenson WG, Wolff L, Wang J, Fukushima P, Mansoor A, et al. In vitro suppression of programmed cell death of B cells by tissue inhibitor of metalloproteinases-1. J. Clin. Investig. 1998;102:2002–2010
  11. Hayakawa T, Yamashita K, Tanzawa K, Uchijima E, Iwata K. Growth-promoting activity of tissue inhibitor of metalloproteinases-1 (TIMP-1) for a wide range of cells. A possible new growth factor in serum. FEBS Lett. 1992;298:29–32
  12. Holten-Andersen MN, Christensen IJ, Nielsen HJ, Lilja H, Murphy G, Jensen V, et al. Measurement of the noncomplexed free fraction of tissue inhibitor of metalloproteinases 1 in plasma by immunoassay. Clin. Chem. 2002;48:1305–1313
  13. Holten-Andersen MN, Christensen IJ, Nielsen HJ, Stephens RW, Jensen V, Nielsen OH, et al. Total levels of tissue inhibitor of metalloproteinases 1 in plasma yield high diagnostic sensitivity and specificity in patients with colon cancer. Clin. Cancer Res. 2002;8:156–164
  14. Holten-Andersen MN, Hansen U, Brunner N, Nielsen HJ, Illemann M, Nielsen BS. Localization of tissue inhibitor of metalloproteinases 1 (TIMP-1) in human colorectal adenoma and adenocarcinoma. Int. J. Cancer. 2005;113:198–206
  15. Holten-Andersen MN, Murphy G, Nielsen HJ, Pedersen AN, Christensen IJ, Hoyer-Hansen G, et al. Quantitation of TIMP-1 in plasma of healthy blood donors and patients with advanced cancer. Br. J. Cancer. 1999;80:495–503
  16. Holten-Andersen MN, Stephens RW, Nielsen HJ, Murphy G, Christensen IJ, Stetler-Stevenson W, et al. High preoperative plasma tissue inhibitor of metalloproteinase-1 levels are associated with short survival of patients with colorectal cancer. Clin. Cancer Res. 2000;6:4292–4299
  17. Inoue H, Mimori K, Shiraishi T, Kataoka A, Sadanaga N, Ueo H, et al. Expression of tissue inhibitor of matrix metalloproteinase-1 in human breast carcinoma. Oncol. Rep. 2000;7:871–874
  18. Kozak M. At least six nucleotides preceding the AUG initiator codon enhance translation in mammalian cells. J. Mol. Biol. 1987;196:947–950
  19. Lemaitre V, D'Armiento J. Matrix metalloproteinases in development and disease. Birth Defects Res. C Embryo Today. 2006;78:1–10
  20. Liu XW, Taube ME, Jung KK, Dong Z, Lee YJ, Roshy S, et al. Tissue inhibitor of metalloproteinase-1 protects human breast epithelial cells from extrinsic cell death: a potential oncogenic activity of tissue inhibitor of metalloproteinase-1. Cancer Res. 2005;65:898–906
  21. Moller SN, Dowell BL, Stewart KD, Jensen V, Larsen L, Lademann U, et al. Establishment and characterization of 7 new monoclonal antibodies to tissue inhibitor of metalloproteinases-1. Tumor Biol. 2005;26:71–80
  22. Murphy G, Houbrechts A, Cockett MI, Williamson RA, O'Shea M, Docherty AJ. The N-terminal domain of tissue inhibitor of metalloproteinases retains metalloproteinase inhibitory activity. Biochemistry. 1991;30:8097–8102
  23. Nakopoulou L, Giannopoulou I, Stefanaki K, Panayotopoulou E, Tsirmpa I, Alexandrou P, et al. Enhanced mRNA expression of tissue inhibitor of metalloproteinase-1 (TIMP-1) in breast carcinomas is correlated with adverse prognosis. J. Pathol. 2002;197:307–313
  24. Offenberg H, Thomsen PD. Functional challenge affects aquaporin mRNA abundance in mouse blastocysts. Mol. Reprod. Dev. 2005;71:422–430
  25. Ouyang DL, Chen JJ, Getzenberg RH, Schoen RE. Noninvasive testing for colorectal cancer: a review. Am. J. Gastroenterol. 2005;100:1393–1403
  26. Ree AH, Florenes VA, Berg JP, Maelandsmo GM, Nesland JM, Fodstad O. High levels of messenger RNAs for tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in primary breast carcinomas are associated with development of distant metastases. Clin. Cancer Res. 1997;3:1623–1628
  27. Schrohl AS, Christensen IJ, Pedersen AN, Jensen V, Mouridsen H, Murphy G, et al. Tumor tissue concentrations of the proteinase inhibitors tissue inhibitor of metalloproteinases-1 (TIMP-1) and plasminogen activator inhibitor type 1 (PAI-1) are complementary in determining prognosis in primary breast cancer. Mol. Cell Proteomics. 2003;2:164–172
  28. Schrohl AS, Holten-Andersen MN, Peters HA, Look MP, Meijer-van Gelder ME, Klijn JG, et al. Tumor tissue levels of tissue inhibitor of metalloproteinase-1 as a prognostic marker in primary breast cancer. Clin. Cancer Res. 2004;10:2289–2298
  29. Schrohl AS, Meijer-van Gelder ME, Holten-Andersen MN, Christensen IJ, Look MP, Mouridsen H, et al. Primary tumour levels of tissue inhibitor of metalloproteinases-1 are predictive of response to chemotherapy in patients with metastatic breast cancer. Clin. Cancer Res. 2006;12:7054–7058
  30. Span PN, Lindberg RL, Manders P, Tjan-Heijnen VC, Heuvel JJ, Beex LV, et al. Tissue inhibitors of metalloproteinase expression in human breast cancer: TIMP-3 is associated with adjuvant endocrine therapy success. J. Pathol. 2004;202:395–402
  31. Stricklin GP, Welgus HG. Human skin fibroblast collagenase inhibitor. Purification and biochemical characterization. J. Biol. Chem. 1983;258:12252–12258
  32. Thaysen-Andersen M, Thogersen IB, Nielsen HJ, Lademann U, Brunner N, Enghild JJ, et al. Rapid and individual-specific glycoprofiling of a low-abundant N-glycosylated protein tissue inhibitor of metalloproteinases-1. Mol. Cell. Proteomics. January 6, 2007;
  33. Venables JP. Unbalanced alternative splicing and its significance in cancer. Bioessays. 2006;28:378–386
  34. Waas ET, Hendriks T, Lomme RM, Wobbes T. Plasma levels of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 correlate with disease stage and survival in colorectal cancer patients. Dis. Colon Rectum. 2005;48:700–710
  35. Westbrook CA, Gasson JC, Gerber SE, Selsted ME, Golde DW. Purification and characterization of human T-lymphocyte-derived erythroid-potentiating activity. J. Biol. Chem. 1984;259:9992–9996
  36. Wurtz SO, Christensen IJ, Schrohl AS, Mouridsen H, Lademann U, Jensen V, et al. Measurement of the uncomplexed fraction of tissue inhibitor of metalloproteinases-1 in the prognostic evaluation of primary breast cancer patients. Mol. Cell. Proteomics. 2005;4:483–491

PII: S1574-7891(07)00033-6

doi: 10.1016/j.molonc.2007.05.002

Molecular Oncology
Volume 1, Issue 2 , Pages 205-215 , September 2007

Article Tools

* Image Usage & Resolution